AVBP vs AZN
AVBP: Arrivent Biopharma is a clinical-stage oncology company dedicated to advancing a pipeline of innovative cancer therapies through global development and strategic in-licensing. AZN: AstraZeneca is a global, science-led biopharmaceutical company focused on transforming patient outcomes in oncology, rare diseases, and chronic conditions through a robust and diverse R&D pipeline.
Side-by-side fundamentals
| Metric | AVBP | AZN | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $18.85 | $168.82 | |
| Market cap | $929M | $254.2B | |
| Net margin FY2025, SEC XBRL | n/a | +17.4% | |
| Gross margin FY2025, SEC XBRL | n/a | +81.9% | |
| Operating margin FY2025, SEC XBRL | n/a | +23.4% | |
| ROE FY2025, SEC XBRL | -54.1% | +21.0% | AZN higher |
| ROA FY2025, SEC XBRL | -49.9% | +9.0% | AZN higher |
| Revenue growth (YoY) FY2025, SEC XBRL | n/a | +8.6% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +9.8% | |
| Dividend yield as of 2026-09-03 | n/a | +2.6% | |
| Dividend streak (yrs) SEC XBRL | 0 | n/a | |
| Beta as of 2026-09-03 | 0.97 | 0.34 | |
| 1-year return as of 2026-10-20 close | -5.7% | +0.6% | AZN higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.